AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Skye Bioscience, Inc.
Video analysis: SKYE
All videosNo video analysis for this stock yet. Request one from our team.
News: SKYE
Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx Therapeutics
Skye Bioscience (NASDAQ: SKYE) and privately held Redx announced a definitive transaction agreement that would combine the companies into a Nasdaq-listed fibrosis-focused biotechnology company named Fibrx Therapeutics. The transaction, unanimously approved by both companies' boards, is expected to close in the fourth quarter of 2026, subject to shareholder approvals, customary closing conditions, approval of the Redx
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, with an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 clinical study Concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional investors Financings expected to fund operations through RXC008 Phase 2 clinical trial – topline data expected H2 2028 Companies to hold a joint conference call on August 14, 2026 at 10 a.m. ET SAN DIEGO and ALDERLEY PARK, United Kingdom, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (“Skye”) (Nasdaq: SKYE), and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, today announced that they have entered into a definitive transaction agreement (the “Transaction Agreement”).
Skye Bioscience (NASDAQ:SKYE) Trading 2.8% Higher – Time to Buy?
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report)'s share price was up 2.8% during mid-day trading on Monday. The stock traded as high as $0.5918 and last traded at $0.5842. Approximately 102,145 shares were traded during trading, a decline of 16% from the average session volume of 122,073 shares. The stock had previously closed
